Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...
Popular GLP-1 medications approved for weight loss, diabetes, and heart disease may have untapped potential to reduce the ...
Approximately 15.5 million Americans have been or currently are on injectable diabetes or weight-loss medications known as ...
A combination of an SGLT-2 inhibitor drug and a moderately calorie-restrictive diet leads to higher rates of type 2 diabetes ...
A new study compares the benefits and risks of taking GLP-1 medications for weight loss, including risks of dementia, ...
A study on GLP1RA medications found that behavioral side effects likely do not result from direct action on GLP1R.
For people with diabetes, the use of GLP-1 RAs is associated with a reduced risk for certain disorders and conditions, including neurocognitive and cardiometabolic disorders, and with an increased ...
Utah Facial Plastics is transforming weight loss with Semaglutide and Tirzepitide, two proven treatments that help regulate ...
A major new study has revealed a long list of benefits and some little-known risks of Ozempic and other GLP-1 medications.
Fortune on MSN10d
Largest-ever Ozempic and GLP-1 drug study finds they lower risk of 42 health conditions, including heart attacks and Alzheimer’s diseaseClearly, those mechanisms can extend well beyond diabetes control or weight loss promotion. “I think the elephant in the room ...
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), used to treat diabetes and for weight loss, may be linked with a reduced risk of substance use and neurocognitive disorders, a US study in people ...
T he newest weight-loss drugs, Wegovy and Zepbound, are incredibly popular. But doctors are still learning about all of the ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback